Roche appoints Janet Hammond to translational medicine role
pharmafile | March 31, 2011 | Appointment | Research and Development |Â Â appointment, research and developmentÂ
Janet Hammond has joined Roche to drive the early clinical development strategy for its virology discovery and translational area.
She said: “I am delighted to be joining Roche. The company is on the cutting edge of research in the areas of virology and translational medicine, and I am very excited to be able to be part of an impressive team of people who are striving to develop new approaches for the treatment of patients with infectious diseases.”
As VP of translational medicine – virology she will be based in the Swiss pharma company’s New Jersey, USA offices and report to Jacques Banchereau, discovery and translational area head for inflammation and virology.
Janet moves to Roche from Valeant Pharmaceuticals International, where she was chief medical officer and senior VP of global medical affairs.
During a 13-year pharma career she has also worked at Bristol-Myers Squibb, as group director of global clinical research in virology and infectious diseases, and GlaxoSmithKline as head of clinical drug discovery virology.
“Janet’s background and experience will be a great addition to our efforts to drive translational medicine as well as virology within Roche as we continue our quest to find new and more effective approaches to drug development, ultimately providing better options for patients,” said Jacques Banchereau.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






